<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US6030790 - Kit for detecting active human parathyroid hormone including two sets of ... - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_8a2b04e7bf975d5171d8e4c0b6365c7a/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_8a2b04e7bf975d5171d8e4c0b6365c7a__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Kit for detecting active human parathyroid hormone including two sets of antibodies or antibody fragments; for diagnosis"><meta name="DC.contributor" content="Knut Adermann" scheme="inventor"><meta name="DC.contributor" content="Dieter Hock" scheme="inventor"><meta name="DC.contributor" content="Markus Magerlein" scheme="inventor"><meta name="DC.contributor" content="Haemopep Pharma Gmbh" scheme="assignee"><meta name="DC.date" content="1995-9-22" scheme="dateSubmitted"><meta name="DC.description" content="The present invention is directed to peptides from the sequence of hPTH(1-37), which contain α-helical amino acid sequence regions and/or non-structured amino acid sequence regions, said peptides being capable of inducing antibodies when injected into animals. Furthermore, the invention is directed to a diagnostic agent and antibodies obtainable by immunizing animals using the peptides according to the invention."><meta name="DC.date" content="2000-2-29" scheme="issued"><meta name="DC.relation" content="US:4508828" scheme="references"><meta name="citation_reference" content="Bowie et al. Science 247:1306 1310, 1990."><meta name="citation_reference" content="Bowie et al. Science 247:1306-1310, 1990."><meta name="citation_reference" content="Daniel et al. Virology 202: 540 549, 1994."><meta name="citation_reference" content="Daniel et al. Virology 202: 540-549, 1994."><meta name="citation_reference" content="Ngo et al. The Protein Folding Problem and Tertiary Structure Prediction, Merz et al., eds., Birkhauser, Boston, pp. 492 495, 1994."><meta name="citation_reference" content="Ngo et al. The Protein Folding Problem and Tertiary Structure Prediction, Merz et al., eds., Birkhauser, Boston, pp. 492-495, 1994."><meta name="citation_reference" content="Nussbaum et al. Chemical Abstracts 96(5), Abstract No. 29060, 1982."><meta name="citation_reference" content="Tampe et al. J. Immunoassay 13(1):1 13, 1992."><meta name="citation_reference" content="Tampe et al. J. Immunoassay 13(1):1-13, 1992."><meta name="citation_patent_number" content="US:6030790"><meta name="citation_patent_application_number" content="US:08/817,547"><link rel="canonical" href="http://www.google.com/patents/US6030790"/><meta property="og:url" content="http://www.google.com/patents/US6030790"/><meta name="title" content="Patent US6030790 - Kit for detecting active human parathyroid hormone including two sets of antibodies or antibody fragments; for diagnosis"/><meta name="description" content="The present invention is directed to peptides from the sequence of hPTH(1-37), which contain α-helical amino acid sequence regions and/or non-structured amino acid sequence regions, said peptides being capable of inducing antibodies when injected into animals. Furthermore, the invention is directed to a diagnostic agent and antibodies obtainable by immunizing animals using the peptides according to the invention."/><meta property="og:title" content="Patent US6030790 - Kit for detecting active human parathyroid hormone including two sets of antibodies or antibody fragments; for diagnosis"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("DKLtU6m9CLKzsQSyloDoDw"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407723702.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("USA"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("DKLtU6m9CLKzsQSyloDoDw"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407723702.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("USA"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us6030790?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US6030790"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=FD5OBAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS6030790&amp;usg=AFQjCNFCPbWdGmNsR9owxNu8x5wcHDpWjA" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US6030790.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US6030790.pdf"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US6030790" style="display:none"><span itemprop="description">The present invention is directed to peptides from the sequence of hPTH(1-37), which contain α-helical amino acid sequence regions and/or non-structured amino acid sequence regions, said peptides being capable of inducing antibodies when injected into animals. Furthermore, the invention is directed...</span><span itemprop="url">http://www.google.com/patents/US6030790?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US6030790 - Kit for detecting active human parathyroid hormone including two sets of antibodies or antibody fragments; for diagnosis</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US6030790 - Kit for detecting active human parathyroid hormone including two sets of antibodies or antibody fragments; for diagnosis" title="Patent US6030790 - Kit for detecting active human parathyroid hormone including two sets of antibodies or antibody fragments; for diagnosis"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US6030790 A</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 08/817,547</td></tr><tr><td class="patent-bibdata-heading">PCT number</td><td class="single-patent-bibdata">PCT/EP1995/003757</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Feb 29, 2000</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Sep 22, 1995</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Sep 28, 1994</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Lapsed</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/DE4434551A1">DE4434551A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE59509914D1">DE59509914D1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0783522A1">EP0783522A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0783522B1">EP0783522B1</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO1996010041A1">WO1996010041A1</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">08817547, </span><span class="patent-bibdata-value">817547, </span><span class="patent-bibdata-value">PCT/1995/3757, </span><span class="patent-bibdata-value">PCT/EP/1995/003757, </span><span class="patent-bibdata-value">PCT/EP/1995/03757, </span><span class="patent-bibdata-value">PCT/EP/95/003757, </span><span class="patent-bibdata-value">PCT/EP/95/03757, </span><span class="patent-bibdata-value">PCT/EP1995/003757, </span><span class="patent-bibdata-value">PCT/EP1995/03757, </span><span class="patent-bibdata-value">PCT/EP1995003757, </span><span class="patent-bibdata-value">PCT/EP199503757, </span><span class="patent-bibdata-value">PCT/EP95/003757, </span><span class="patent-bibdata-value">PCT/EP95/03757, </span><span class="patent-bibdata-value">PCT/EP95003757, </span><span class="patent-bibdata-value">PCT/EP9503757, </span><span class="patent-bibdata-value">US 6030790 A, </span><span class="patent-bibdata-value">US 6030790A, </span><span class="patent-bibdata-value">US-A-6030790, </span><span class="patent-bibdata-value">US6030790 A, </span><span class="patent-bibdata-value">US6030790A</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Knut+Adermann%22">Knut Adermann</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Dieter+Hock%22">Dieter Hock</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Markus+Magerlein%22">Markus Magerlein</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Haemopep+Pharma+Gmbh%22">Haemopep Pharma Gmbh</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US6030790.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6030790.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6030790.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (1),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (9),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (30),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (18),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (12)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=FD5OBAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/6030790&usg=AFQjCNE2aEu5gWQv_asg2IBVQm9cHBdaTw">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=FD5OBAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D6030790&usg=AFQjCNHtvRC-AwfWDoZR7wQ1_fNuqDRKaw">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=FD5OBAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D6030790A%26KC%3DA%26FT%3DD&usg=AFQjCNFH8Wittw5TTr_CIyi2U6QEpe_VfA">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT128971480" lang="EN" load-source="ifi">Kit for detecting active human parathyroid hormone including two sets of antibodies or antibody fragments; for diagnosis</invention-title></span><br><span class="patent-number">US 6030790 A</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA38038412" lang="EN" load-source="patent-office"> <div class="abstract">The present invention is directed to peptides from the sequence of hPTH(1-37), which contain α-helical amino acid sequence regions and/or non-structured amino acid sequence regions, said peptides being capable of inducing antibodies when injected into animals. Furthermore, the invention is directed to a diagnostic agent and antibodies obtainable by immunizing animals using the peptides according to the invention.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(19)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6030790-0.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6030790-0.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6030790-1.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6030790-1.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6030790-2.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6030790-2.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6030790-3.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6030790-3.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6030790-4.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6030790-4.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6030790-5.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6030790-5.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6030790-6.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6030790-6.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6030790-7.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6030790-7.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6030790-8.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6030790-8.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6030790-9.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6030790-9.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6030790-10.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6030790-10.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6030790-11.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6030790-11.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6030790-12.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6030790-12.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6030790-13.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6030790-13.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6030790-14.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6030790-14.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6030790-15.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6030790-15.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6030790-16.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6030790-16.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6030790-17.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6030790-17.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6030790-18.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6030790-18.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(25)</span></span></div><div class="patent-text"><div mxw-id="PCLM5529493" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>We claim:</claim-statement> <div class="claim"> <div num="1" class="claim">
      <div class="claim-text">1. A kit for detecting active human parathyroid hormone (hPTH) comprising a container and a first group of antibodies or antibody fragments and a second group of antibodies or antibody fragments, wherein the first group selectively binds a peptide of hPTH selected from the group consisting of peptides having SEQ. ID. Nos. 1-6 and the second group selectively binds hPTH at an epitope contained within amino acids 24 to 37.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="2" class="claim">
      <div class="claim-text">2. The kit of claim 1, wherein the second group of antibodies or antibody fragments selectively binds a peptide of hPTH selected from the group consisting of peptides having SEQ. ID. Nos. 18-36.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="3" class="claim">
      <div class="claim-text">3. The kit of claim 1, wherein the first group of antibodies or antibody fragments selectively bind peptides of hPTH having SEQ. ID. No. 1.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="4" class="claim">
      <div class="claim-text">4. The kit of claim 1, wherein the first group of antibodies or antibody fragments selectively bind peptides of hPTH having SEQ. ID. No. 2.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="5" class="claim">
      <div class="claim-text">5. The kit of claim 1, wherein the first group of antibodies or antibody fragments selectively bind peptides of hPTH having SEQ. ID. No. 3.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="6" class="claim">
      <div class="claim-text">6. The kit of claim 1, wherein the first group of antibodies or antibody fragments selectively bind peptides of hPTH having SEQ. ID. No. 4.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="7" class="claim">
      <div class="claim-text">7. The kit of claim 1, wherein the first group of antibodies or antibody fragments selectively bind peptides of hPTH having SEQ. ID. No. 5.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="8" class="claim">
      <div class="claim-text">8. The kit of claim 1, wherein the first group of antibodies or antibody fragments selectively bind peptides of hPTH having SEQ. ID. No. 6.</div>
    </div>
    </div> <div class="claim"> <div num="9" class="claim">
      <div class="claim-text">9. An immunological method of detecting active human parathyroid hormone (hPTH) in a sample comprising:<div class="claim-text">contacting the sample with a first antibody or antibody fragment which selectively binds a peptide of hPTH selected from the group consisting of peptides having SEQ. ID. Nos. 1-6, wherein the first antibody or antibody fragment binds hPTH in the sample;</div> <div class="claim-text">contacting the sample with a second antibody or antibody fragment which selectively binds hPTH at an epitope contained within amino acids 24 to 37; wherein the second antibody or antibody fragment binds to hPTH bound by the first antibody or antibody fragment; and</div> <div class="claim-text">detecting the binding of the first and second antibodies or antibody fragments, wherein the binding of the first and second antibodies or antibody fragments indicates the presence of active hPTH in the sample.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="10" class="claim">
      <div class="claim-text">10. The method of claim 9, wherein the second antibody or antibody fragment selectively binds a peptide of hPTH selected from the group consisting of peptides having SEQ. ID. Nos. 18-36.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="11" class="claim">
      <div class="claim-text">11. The method of claim 9, wherein the first antibody or antibody fragment selectively binds peptides of hPTH having SEQ. ID. No. 1.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="12" class="claim">
      <div class="claim-text">12. The method of claim 9, wherein the first antibody or antibody fragment selectively binds peptides of hPTH having SEQ. ID. No. 2.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="13" class="claim">
      <div class="claim-text">13. The method of claim 9, wherein the first antibody or antibody fragment selectively binds peptides of hPTH having SEQ. ID. No. 3.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="14" class="claim">
      <div class="claim-text">14. The method of claim 9, wherein the first antibody or antibody fragment selectively binds peptides of hPTH having SEQ. ID. No. 4.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="15" class="claim">
      <div class="claim-text">15. The method of claim 9, wherein the first antibody or antibody fragment selectively binds peptides of hPTH having SEQ. ID. No. 5.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="16" class="claim">
      <div class="claim-text">16. The method of claim 9, wherein the first antibody or antibody fragment selectively binds peptides of hPTH having SEQ. ID. No. 6.</div>
    </div>
    </div> <div class="claim"> <div num="17" class="claim">
      <div class="claim-text">17. A composition comprising an antibody or antibody fragment and a suitable carrier, wherein the antibody or antibody fragment selectively binds a peptide of human parathyroid hormone (hPTH) selected from the group consisting of peptides having SEQ. ID. Nos. 1-6.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="18" class="claim">
      <div class="claim-text">18. The composition of claim 17, wherein the composition further comprises a second antibody or antibody fragment, wherein the second antibody or antibody fragment selectively binds hPTH at an epitope contained within amino acids 24 to 37.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="19" class="claim">
      <div class="claim-text">19. The composition of claim 17, wherein the second antibody or antibody fragment selectively binds a peptide of hPTH selected from the group consisting of peptides having SEQ. ID. Nos. 18-36.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="20" class="claim">
      <div class="claim-text">20. The composition of claim 17, wherein the antibody or antibody fragment selectively binds peptides of hPTH having SEQ. ID. No. 1.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="21" class="claim">
      <div class="claim-text">21. The composition of claim 17, wherein the antibody or antibody fragment selectively binds peptides of hPTH having SEQ. ID. No. 2.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="22" class="claim">
      <div class="claim-text">22. The composition of claim 17, wherein the antibody or antibody fragment selectively binds peptides of hPTH having SEQ. ID. No. 3.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="23" class="claim">
      <div class="claim-text">23. The composition of claim 17, wherein the antibody or antibody fragment selectively binds peptides of hPTH having SEQ. ID. No. 4.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="24" class="claim">
      <div class="claim-text">24. The composition of claim 17, wherein the antibody or antibody fragment selectively binds peptides pf hPTH having SEQ. ID. No. 5.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="25" class="claim">
      <div class="claim-text">25. The composition of claim 17, wherein the antibody or antibody fragment selectivley binds peptides of hPTH having SEQ. ID. No. 6.</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES67436476" lang="EN" load-source="patent-office" class="description">
    <p>This application was filed under 35 U.S.C. § 371 and claims priority from PCT/EP95/03757, filed Sep. 22, 1995.</p>
    <p>The present invention relates to peptides from the sequence of hPTH(1-37), and the use of said peptides in the preparation of an agent for diagnosing biologically active hPTH.</p>
    <p>Human parathyroid hormone (hPTH), a linear polypeptide having 84 amino acids, plays an important role in the regulation of the calcium metabolism. The metabolism of this hormone gives rise to a large number of C-terminal fragments, the biological functions of which have not yet been elucidated. The hPTH(1-37) has been established as a circulating N-terminal fragment (EP-A 0 349 545). This fragment has the full biological activity of the entire hormone. However, upon loss of the first amino acid, serine, the activity significantly decreases and is lost completely without the first two amino acids, serine and valine.</p>
    <p>Serum levels in the range of 10<sup>-12</sup> mol/l are measured for the intact hormone hPTH(1-84) and for the N-terminal fragment. Immunological measuring procedures are employed to determine such low concentrations. Here, the most valid results are provided by measuring procedures according to the double antibody or sandwich principle (e.g., the two-site radioimmunometric assay, IRMA, or the sandwich enzyme-linked immuno sorbent assay, Sandwich ELISA). For hPTH(1-84), such assays are commercially available. For the measurement of hPTH(1-34), an assay according to the double antibody principle is not known.</p>
    <p>Here, two antibodies are required. In order to avoid mutual steric hindrance, they must be capable of recognizing antigen epitopes located at a sufficient distance from each other. When immunizing using the intact antigen, a heterogeneous mixture of various antibodies is obtained, which first must be subjected to an expensive purification in order to conduct a sandwich assay. According to theoretical calculations by B. A. Jameson and H. Wolf, The Antigenic Index: A Novel Algorithm for Predicting Antigenic Determinants, CABIOS 4, p. 181-186, 1988; it has been possible so far to detect a preferred sequence having immunogenic activity in the region of the amino acids 7-14 at the N-terminus. Immunization with N-terminal fragments according to established methods predominantly results in antibodies which, as has been described for hPTH(1-34) (J. Tampe, P. Brozio, H. E. Manneck, A. Miβbichler, E. Blind, K. B. Millers, H. SchmidtGayk, and F. P. Armbruster, Characterisation of Antibodies Against Human N-Terminal Parathyroid Hormone by Epitope Mapping; J. Immunoassay 13, p. 1-13, 1992), bind in the region of these amino acids. However, these antibodies are not capable of discriminating between biologically active and biologically inactive PTH(1-84) or fragments thereof lacking the first two amino acids serine and valine.</p>
    <p>The technical problem which this invention is based upon is to provide peptides by means of which it is possible to eliminate the above-mentioned drawbacks in the diagnosis of biologically active hPTH.</p>
    <p>Surprisingly, the technical problem described above is solved by means of the following peptides from the sequence of hPTH(1-37):</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">hPTH 1-10 SEQ I.D. NO.1NH<sub>2</sub> -Ser<sup>1</sup> -Val<sup>2</sup> -Ser<sup>3</sup> -Glu<sup>4</sup> -Ile<sup>5</sup> -Gln<sup>6</sup> -Leu<sup>7</sup> -Met<sup>8</sup> -His<sup>9</sup> -Asn<sup>10</sup> -OH                                    (1)hPTH 1-9 SEQ I.D. NO.2NH<sub>2</sub> -Ser<sup>1</sup> -Val<sup>2</sup> -Ser<sup>3</sup> -Glu<sup>4</sup> -Ile<sup>5</sup> -Gln<sup>6</sup> -Leu<sup>7</sup> -Met<sup>8</sup> -His<sup>9</sup> -OH    (2)hPTH 1-8 SEQ I.D. NO.3NH<sub>2</sub> -Ser<sup>1</sup> -Val<sup>2</sup> -Ser<sup>3</sup> -Glu<sup>4</sup> -Ile<sup>5</sup> -Gln<sup>6</sup> -Leu<sup>7</sup> -Met<sup>8</sup> -OH               (3)hPTH 1-7 SEQ I.D. NO.4NH<sub>2</sub> -Ser<sup>1</sup> -Val<sup>2</sup> -Ser<sup>3</sup> -Glu<sup>4</sup> -Ile<sup>5</sup> -Gln<sup>6</sup> -Leu<sup>7</sup> -OH                          (4)hPTH 1-6 SEQ I.D. NO.5NH<sub>2</sub> -Ser<sup>1</sup> -Val<sup>2</sup> -Ser<sup>3</sup> -Glu<sup>4</sup> -Ile<sup>5</sup> -Gln<sup>6</sup> -OH                                     (5)hPTH 1-5 SEQ I.D. NO.6NH<sub>2</sub> -Ser<sup>1</sup> -Val<sup>2</sup> -Ser<sup>3</sup> -Glu<sup>4</sup> -Ile<sup>5</sup> -OH                                    (6)hPTH 9-18 SEQ I.D. NO.7NH<sub>2</sub> -His<sup>9</sup> -Asn<sup>10</sup> -Leu<sup>11</sup> -Gly<sup>12</sup> -Lys<sup>13</sup>-His<sup>14</sup> -Leu<sup>15</sup> -Asn<sup>16</sup> -Ser<sup>17</sup> -Met<sup>18</sup> -OH                                    (7)hPTH 10-18 SEQ I.D. NO.8NH<sub>2</sub> -Asn<sup>10</sup> -Leu<sup>11</sup> -Gly<sup>12</sup> -Lys<sup>13</sup> -His<sup>14</sup>-Leu<sup>15</sup> -Asn<sup>16</sup> -Ser<sup>17</sup> -Met<sup>18</sup> -OH                                    (8)hPTH 11-18 SEQ I.D. NO.9NH<sub>2</sub> -Leu<sup>11</sup> -Gly<sup>12</sup> -Lys<sup>13</sup> -His<sup>14</sup> -Leu<sup>15</sup>-Asn<sup>16</sup> -Ser<sup>17</sup> -Met<sup>18</sup> -OH  (9)hPTH 12-18 SEQ I.D. NO.10NH<sub>2</sub> -Gly<sup>12</sup> -Lys<sup>13</sup> -His<sup>14</sup> -Leu<sup>15</sup> -Asn<sup>16</sup>-Ser<sup>17</sup> -Met<sup>18</sup> -OH              (10)hPTH 13-18 SEQ I.D. NO.11NH<sub>2</sub> -Lys<sup>13</sup> -His<sup>14</sup> -Leu<sup>15</sup> -Asn<sup>16</sup> -Ser<sup>17</sup>-Met<sup>18</sup> -OH                          (11)hPTH 14-18 SEQ I.D. NO.12NH<sub>2</sub> -His<sup>14</sup> -Leu<sup>15</sup> -Asn<sup>16</sup> -Ser<sup>17</sup> -Met<sup>18</sup>                                    (12)hPTH 9-17 SEQ I.D. NO.13NH<sub>2</sub> -His<sup>9</sup> -Asn<sup>10</sup> -Leu<sup>11</sup> -Gly<sup>12</sup> -Lys<sup>13</sup>-His<sup>14</sup> -Leu<sup>15</sup> -Asn<sup>16</sup> -Ser<sup>17</sup> -OH                                    (13)hPTH 9-16 SEQ I.D. NO.14NH<sub>2</sub> -His<sup>9</sup> -Asn<sup>10</sup> -Leu<sup>11</sup> -Gly<sup>12</sup> -Lys<sup>13</sup>-His<sup>14</sup> -Leu<sup>15</sup> -Asn<sup>16</sup> -OH  (14)hPTH 9-15 SEQ I.D. NO.15NH<sub>2</sub> -His<sup>9</sup> -Asn<sup>10</sup> -Leu<sup>11</sup> -Gly<sup>12</sup> -Lys<sup>13</sup>-His<sup>14</sup> -Leu<sup>15</sup> -OH              (15)hPTH 9-14 SEQ I.D. NO.16NH<sub>2</sub> -His<sup>9</sup> -Asn<sup>10</sup> -Leu<sup>11</sup> -Gly<sup>12</sup> -Lys<sup>13</sup>-His<sup>14</sup> -OH                          (16)hPTH 9-13 SEQ I.D. NO.17NH<sub>2</sub> -His<sup>9</sup> -Asn<sup>10</sup> -Leu<sup>11</sup> -Gly<sup>12</sup> -Lys<sup>13</sup>                                    (17)hPTH 24-37 SEQ I.D. NO.18NH<sub>2</sub> -Leu<sup>24</sup> -Arg<sup>25</sup> -Lys<sup>26</sup> -Lys<sup>27</sup> -Leu<sup>28</sup>-Gln<sup>29</sup> -Asp<sup>30</sup> -Val<sup>31</sup> -His<sup>32</sup> -Asn<sup>33</sup> -Phe<sup>34</sup> -Val<sup>35</sup> -Ala<sup>36</sup> -Leu<sup>37</sup> -OH                                    (18)hPTH 25-37 SEQ I.D. NO.19NH<sub>2</sub> -Arg<sup>25</sup> -Lys<sup>26</sup> -Lys<sup>27</sup> -Leu<sup>28</sup> -Gln<sup>29</sup>-Asp<sup>30</sup> -Val<sup>31</sup> -His<sup>32</sup> -Asn<sup>33</sup> -Phe<sup>34</sup> -Val<sup>35</sup> -Ala<sup>36</sup> -Leu<sup>37</sup> -OH                                    (19)hPTH 26-37 SEQ I.D. NO.20NH<sub>2</sub> -Lys<sup>26</sup> -Lys<sup>27</sup> -Leu<sup>28</sup> -Gln<sup>29</sup> -Asp<sup>30</sup>-Val<sup>31</sup> -His<sup>32</sup> -Asn<sup>33</sup> -Phe<sup>34</sup> -Val<sup>35</sup> -Ala<sup>36</sup> -Leu<sup>37</sup> -OH                                    (20)hPTH 27-37 SEQ I.D. NO.21NH<sub>2</sub> -Lys<sup>27</sup> -Leu<sup>28</sup> -Gln<sup>29</sup> -Asp<sup>30</sup> -Val<sup>31</sup>-His<sup>32</sup> -Asn<sup>33</sup> -Phe<sup>34</sup> -Val<sup>35</sup> -Ala<sup>36</sup> -Leu<sup>37</sup> -OH                                    (21)hPTH 28-37 SEQ I.D. NO.22NH<sub>2</sub> -Leu<sup>28</sup> -Gln<sup>29</sup> -Asp<sup>30</sup> -Val<sup>31</sup> -His<sup>32</sup>-Asn<sup>33</sup> -Phe<sup>34</sup> -Val<sup>35</sup> -Ala<sup>36</sup> -Leu<sup>37</sup> -OH                                    (22)hPTH 29-37 SEQ I.D. NO.23NH<sub>2</sub> -Gln<sup>29</sup> -Asp<sup>30</sup> -Val<sup>31</sup> -His<sup>32</sup> -Asn<sup>33</sup>-Phe<sup>34</sup> -Val<sup>35</sup> -Ala<sup>36</sup> -Leu<sup>37</sup> -OH                                    (23)hPTH 30-37 SEQ I.D. NO.24NH<sub>2</sub> -Asp<sup>30</sup> -Val<sup>31</sup> -His<sup>32</sup> -Asn<sup>33</sup> -Phe<sup>34</sup>-Val<sup>35</sup> -Ala<sup>36</sup> -Leu<sup>37</sup> -OH  (24)hPTH 31-37 SEQ I.D. NO.25NH<sub>2</sub> -Val<sup>31</sup> -His<sup>32</sup> -Asn<sup>33</sup> -Phe<sup>34</sup> -Val<sup>35</sup>-Ala<sup>36</sup> -Leu<sup>37</sup> -OH              (25)hPTH 32-37 SEQ I.D. NO.26NH<sub>2</sub> -His<sup>32</sup> -Asn<sup>33</sup> -Phe<sup>34</sup> -Val<sup>35</sup> -Ala<sup>36</sup>-Leu<sup>37</sup> -OH                          (26)hPTH 33-37 SEQ I.D. NO.27NH<sub>2</sub> -Asn<sup>33</sup> -Phe<sup>34</sup> -Val<sup>35</sup> -Ala<sup>36</sup> -Leu<sup>37</sup>                                    (27)hPTH 24-36 SEQ I.D. NO.28NH<sub>2</sub> -Leu<sup>24</sup> -Arg<sup>25</sup> -Lys<sup>26</sup> -Lys<sup>27</sup> -Leu<sup>28</sup>-Gln<sup>29</sup> -Asp<sup>30</sup> -Val<sup>31</sup> -His<sup>32</sup> -Asn<sup>33</sup> -Phe<sup>34</sup> -Val<sup>35</sup> -Ala<sup>36</sup> -OH   (28)hPTH 24-35 SEQ I.D. NO.29NH<sub>2</sub> -Leu<sup>24</sup> -Arg<sup>25</sup> -Lys<sup>26</sup> -Lys<sup>27</sup> -Leu<sup>28</sup>-Gln<sup>29</sup> -Asp<sup>30</sup> -Val<sup>31</sup> -His<sup>32</sup> -Asn<sup>33</sup> -Phe<sup>34</sup> -Val<sup>35</sup> -OH               (29)hPTH 24-34 SEQ I.D. NO.30NH<sub>2</sub> -Leu<sup>24</sup> -Arg<sup>25</sup> -Lys<sup>26</sup> -Lys<sup>27</sup> -Leu<sup>28</sup>-Gln<sup>29</sup> -Asp<sup>30</sup> -Val<sup>31</sup> -His<sup>32</sup> -Asn<sup>33</sup> -Phe<sup>34</sup> -OH                           (30)hPTH 24-33 SEQ I.D. NO.31NH<sub>2</sub> -Leu<sup>24</sup> -Arg<sup>25</sup> -Lys<sup>26</sup> -Lys<sup>27</sup> -Leu<sup>28</sup>-Gln<sup>29</sup> -Asp<sup>30</sup> -Val<sup>31</sup> -His<sup>32</sup> -Asn<sup>33</sup> -OH                                    (31)hPTH 24-32 SEQ I.D. NO.32NH<sub>2</sub> -Leu<sup>24</sup> -Arg<sup>25</sup> -Lys<sup>26</sup> -Lys<sup>27</sup> -Leu<sup>28</sup>-Gln<sup>29</sup> -Asp<sup>30</sup> -Val<sup>31</sup> -His<sup>32</sup> -OH                                    (32)hPTH 24-31 SEQ I.D. NO.33NH<sub>2</sub> -Leu<sup>24</sup> -Arg<sup>25</sup> -Lys<sup>26</sup> -Lys<sup>27</sup> -Leu<sup>28</sup>-Gln<sup>29</sup> -Asp<sup>30</sup> -Val<sup>31</sup> -OH  (33)hPTH 24-29 SEQ I.D. NO.34NH<sub>2</sub> -Leu<sup>24</sup> -Arg<sup>25</sup> -Lys<sup>26</sup> -Lys<sup>27</sup> -Leu<sup>28</sup>-Gln<sup>29</sup> -OH                          (34)hPTH 24-38 SEQ I.D. NO.35NH<sub>2</sub> -Leu<sup>24</sup> -Arg<sup>25</sup> -Lys<sup>26</sup> -Lys<sup>27</sup> -Leu<sup>28</sup>                                    (35)</pre>
    
    <p>The indicated sequences represent essential features of the secondary structure in their primary structure, as can be demonstrated by supporting NMR data. One precondition to this end was a determination of the PTH(1-37) secondary structure in physiological solution.</p>
    <p>The above-mentioned regions of conspicuous structure have good immunogenic activity. Antibodies are formed, binding to the first amino acids of the N-terminus. Deficiency of only two amino acids gives rise to a substantial loss in affinity. Because these amino acids are indispensable for the biological activity to arise, it is possible by using the peptides of the invention to obtain antibodies recognizing only hPTH and fragments thereof which are biologically active.</p>
    <p>Furthermore, antibodies can be produced which detect the mid-region 9-15, as well as antibodies giving C-terminal binding in the region of the amino acids 30-37. According to the invention, it is therefore possible to produce antibodies against hPTH(1-37) regions which, according to theoretical calculations, do not exhibit immunogenic activity within the entire molecule. In addition, these regions are separated from each other by such a far distance that no steric hindrance is present which would prevent simultaneous binding of two antibodies.</p>
    <p>In preferred embodiments, the peptides may be modified at the N-terminal end, in the side-chain and/or at the C-terminal end, namely, taking the form of acetylation, amidation, phosphorylation and/or glycosylation products.</p>
    <p>Eventually, the peptides of the invention may also be bound to carrier proteins such as hemocyanin, thyroglobulin, bovine serum albumin, ovalbumin, or mouse serum albumin etc. Binding to the carrier proteins is preferably effected using carbodiimide or formaldehyde.</p>
    <p>The peptides of the invention may be used in the preparation of a diagnostic agent. The diagnostic agent of the invention can be obtained using the per se known immunization of animals with at least one of the peptides according to the invention. Following immunization, an immunoglobulin fraction can be isolated from the immunized animals, which contains antibody fractions having an antibody titer against at least one of the peptides of the invention. The invention is also directed to the antibodies thus obtained. In addition to the complete antibodies consisting of F<sub>ab</sub> and F<sub>c</sub>, fragments thereof such as F<sub>ab</sub> or fragments of the antibodies being idiotypes of peptide epitopes may also be used in an alternative embodiment.</p>
    <p>The peptides according to the invention are suitable for preparing an agent for the diagnosis of biologically active hPTH(1-37).</p>
    <p>Referring to the following examples, the invention will be described in more detail.</p>
    <heading>EXAMPLE 1</heading> <p>Solid-Phase Synthesis of Peptides</p>
    <p>The method of the invention for synthesizing the peptides is based on the peptide synthesis using a solid support. Each of the C-terminal amino acids is bound to the support material in the presence of dicyclohexylcarbodiimide and dimethylaminopyridine. Wang resin or similar resins are used as support material for the syntheses.</p>
    <p>The following derivatives of L-amino acids are used in the synthesis of the sequence, starting from the peptidyl resin as specified: a) hPTH(1-10) Seq. I.D. No. 1: Fmoc-Asn(Trt)-Wang resin, Fmoc-His(Trt)-OH, Fmoc-Met-OH, Fmoc-Leu-OH, Fmoc-Gln(Trt)-OH, Fmoc-Ile-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Val-OH, Boc-Ser(tBu)-OH; b) hPTH(9-18) Seq. I.D. No. 7): Fmoc-Met-Wang resin, Fmoc-Ser(tBu)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Leu-OH, Fmoc-His(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Gly-OH, Fmoc-Leu-OH, Fmoc-Asn(Trt)-OH, Boc-His(Trt)-OH; c) hPTH(24-37) Seq. I.D. No. 18: Fmoc-Leu-Wang resin, Fmoc-Ala-OH, Fmoc-Val-OH, Fmoc-Phe-OH, Fmoc-Asn(Trt)-OH, Fmoc-His(Trt)-OH, Fmoc-Val-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Leu-OH.</p>
    <p>The synthesis may be carried out by in situ activation using 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) or derivatives thereof, or benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP) or derivatives thereof in the presence of diisopropylethylamine or N-methylmorpholine and 1-hydroxybenzotriazole, using a four- to tenfold excess of Fmoc-L-amino acid during the coupling reactions in N,N-dimethylformamide, N,N-dimethylacetamide or N-methylpyrrolidone. Removal of the Fmoc groups is effected using 20% piperidine or 2% piperidine and 2% 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in N,N-dimethylformamide, N,N-dimethylacetamide or N-methylpyrrolidone. Following synthesis, the resins are washed with 2-propanol and dichloromethane and dried to constant weight in a high vacuum.</p>
    <p>Removal from the support and deprotection are carried out by reacting the peptidyl resin with trifluoroacetic acid containing 5% scavenger, water, ethanediol, phenol or thioanisole for 30-90 minutes at room temperature, filtrating, washing with trifluoroacetic acid, and subsequently precipitating with tert-butyl methyl ether. The precipitate is lyophilized from aqueous solution.</p>
    <heading>EXAMPLE 2</heading> <p>Purification and Analysis</p>
    <p>The raw products are purified by chromatography on a C18 reversed phase column (10 μm, buffer A: 0.01 N HCl in water; buffer B: 20% isopropanol, 30% methanol, 50% water, 0.01 N HCl; gradient: 10-80% within 60 minutes; detection at 230 nm).</p>
    <p>The purity of the products is determined using mass spectrometry and C18 reversed phase chromatography.</p>
    <heading>EXAMPLE 3</heading> <p>Coupling to Carrier Protein</p>
    <p>Used as carrier proteins are hemocyanin, thyroglobulin, bovine serum albumin, ovalbumin, or mouse serum albumin. Coupling is performed according to the carbodiimide method by way of the carboxyl groups of the peptides. The peptide is activated in aqueous solution by reaction with 1-ethyl-3-(3-methylaminopropyl)carbodiimide hydrochloride for 5 minutes. Coupling is effected by adding the activated peptide to an aqueous solution of the carrier. The molar ratio is 1 peptide 50 amino acids of the carrier protein. The reaction takes 4 hours.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">__________________________________________________________________________#             SEQUENCE LISTING- (1) GENERAL INFORMATION:-    (iii) NUMBER OF SEQUENCES: 36- (2) INFORMATION FOR SEQ ID NO: 1:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 10 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no#1:   (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Ser Val Ser Glu Ile Gln Leu Met His Asn#                10- (2) INFORMATION FOR SEQ ID NO: 2:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 9 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:- Ser Val Ser Glu Ile Gln Leu Met His1               5- (2) INFORMATION FOR SEQ ID NO: 3:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 8 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:- Ser Val Ser Glu Ile Gln Leu Met1               5- (2) INFORMATION FOR SEQ ID NO: 4:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 7 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:- Ser Val Ser Glu Ile Gln Leu1               5- (2) INFORMATION FOR SEQ ID NO: 5:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 6 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:- Ser Val Ser Glu Ile Gln1               5- (2) INFORMATION FOR SEQ ID NO: 6:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 5 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:- Ser Val Ser Glu Ile1               5- (2) INFORMATION FOR SEQ ID NO: 7:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 10 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:- His Asn Leu Gly Lys His Leu Asn Ser Met#                10- (2) INFORMATION FOR SEQ ID NO: 8:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 9 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:- Asn Leu Gly Lys His Leu Asn Ser Met1               5- (2) INFORMATION FOR SEQ ID NO: 9:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 8 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:- Leu Gly Lys His Leu Asn Ser Met1               5- (2) INFORMATION FOR SEQ ID NO: 10:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 7 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:- Gly Lys His Leu Asn Ser Met1               5- (2) INFORMATION FOR SEQ ID NO: 11:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 6 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:- Lys His Leu Asn Ser Met1               5- (2) INFORMATION FOR SEQ ID NO: 12:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 5 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:- His Leu Asn Ser Met1               5- (2) INFORMATION FOR SEQ ID NO: 13:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 9 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:- His Asn Leu Gly Lys His Leu Asn Ser1               5- (2) INFORMATION FOR SEQ ID NO: 14:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 8 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:- His Asn Leu Gly Lys His Leu Asn1               5- (2) INFORMATION FOR SEQ ID NO: 15:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 7 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:- His Asn Leu Gly Lys His Leu1               5- (2) INFORMATION FOR SEQ ID NO: 16:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 6 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:- His Asn Leu Gly Lys His1               5- (2) INFORMATION FOR SEQ ID NO: 17:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 5 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:- His Asn Leu Gly Lys1               5- (2) INFORMATION FOR SEQ ID NO: 18:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 14 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:- Leu Arg Lys Lys Leu Gln Asp Val His Asn Ph - #e Val Ala Leu#                10- (2) INFORMATION FOR SEQ ID NO: 19:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 13 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:- Arg Lys Lys Leu Gln Asp Val His Asn Phe Va - #l Ala Leu#                10- (2) INFORMATION FOR SEQ ID NO: 20:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 12 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:- Lys Lys Leu Gln Asp Val His Asn Phe Val Al - #a Leu#                10- (2) INFORMATION FOR SEQ ID NO: 21:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 11 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:- Lys Leu Gln Asp Val His Asn Phe Val Ala Le - #u#                10- (2) INFORMATION FOR SEQ ID NO: 22:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 10 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:- Leu Gln Asp Val His Asn Phe Val Ala Leu#                10- (2) INFORMATION FOR SEQ ID NO: 23:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 9 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:- Gln Asp Val His Asn Phe Val Ala Leu1               5- (2) INFORMATION FOR SEQ ID NO: 24:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 8 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:- Asp Val His Asn Phe Val Ala Leu1               5- (2) INFORMATION FOR SEQ ID NO: 25:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 7 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:- Val His Asn Phe Val Ala Leu1               5- (2) INFORMATION FOR SEQ ID NO: 26:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 6 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:- His Asn Phe Val Ala Leu1               5- (2) INFORMATION FOR SEQ ID NO: 27:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 5 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:- Asn Phe Val Ala Leu1               5- (2) INFORMATION FOR SEQ ID NO: 28:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 13 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:- Leu Arg Lys Lys Leu Gln Asp Val His Asn Ph - #e Val Ala#                10- (2) INFORMATION FOR SEQ ID NO: 29:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 12 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:- Leu Arg Lys Lys Leu Gln Asp Val His Asn Ph - #e Val#                10- (2) INFORMATION FOR SEQ ID NO: 30:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 11 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:- Leu Arg Lys Lys Leu Gln Asp Val His Asn Ph - #e#                10- (2) INFORMATION FOR SEQ ID NO: 31:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 10 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:- Leu Arg Lys Lys Leu Gln Asp Val His Asn#                10- (2) INFORMATION FOR SEQ ID NO: 32:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 9 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:- Leu Arg Lys Lys Leu Gln Asp Val His1               5- (2) INFORMATION FOR SEQ ID NO: 33:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 8 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:- Leu Arg Lys Lys Leu Gln Asp Val1               5- (2) INFORMATION FOR SEQ ID NO: 34:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 7 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:- Leu Arg Lys Lys Leu Gln Asp1               5- (2) INFORMATION FOR SEQ ID NO: 35:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 6 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:- Leu Arg Lys Lys Leu Gln1               5- (2) INFORMATION FOR SEQ ID NO: 36:-      (i) SEQUENCE CHARACTERISTICS:#acids    (A) LENGTH: 5 amino     (B) TYPE: amino acid     (C) STRANDEDNESS: unknown     (D) TOPOLOGY: unknown-     (ii) MOLECULE TYPE: peptide-    (iii) HYPOTHETICAL: no-     (iv) ANTI-SENSE: no- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:- Leu Arg Lys Lys Leu1               5__________________________________________________________________________</pre>
    
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4508828">US4508828</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 21, 1983</td><td class="patent-data-table-td patent-date-value">Apr 2, 1985</td><td class="patent-data-table-td ">Immuno Nuclear Corporation</td><td class="patent-data-table-td ">Bioassay of parathyroid hormone</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Bowie et al. Science 247:1306 1310, 1990.</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Bowie et al. Science 247:1306-1310, 1990.</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Daniel et al. Virology 202: 540 549, 1994.</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Daniel et al. Virology 202: 540-549, 1994.</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Ngo et al. The Protein Folding Problem and Tertiary Structure Prediction, Merz et al., eds., Birkhauser, Boston, pp. 492 495, 1994.</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ngo et al. The Protein Folding Problem and Tertiary Structure Prediction, Merz et al., eds., Birkhauser, Boston, pp. 492-495, 1994.</td></tr><tr><td class="patent-data-table-td ">7</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Nussbaum et al. Chemical Abstracts 96(5), Abstract No. 29060, 1982.</td></tr><tr><td class="patent-data-table-td ">8</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Tampe et al. J. Immunoassay 13(1):1 13, 1992.</td></tr><tr><td class="patent-data-table-td ">9</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Tampe et al. J. Immunoassay 13(1):1-13, 1992.</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6524788">US6524788</a></td><td class="patent-data-table-td patent-date-value">Nov 2, 2001</td><td class="patent-data-table-td patent-date-value">Feb 25, 2003</td><td class="patent-data-table-td ">Thomas L. Cantor</td><td class="patent-data-table-td ">Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6689566">US6689566</a></td><td class="patent-data-table-td patent-date-value">Jan 14, 1999</td><td class="patent-data-table-td patent-date-value">Feb 10, 2004</td><td class="patent-data-table-td ">Scantibodies Laboratory, Inc.</td><td class="patent-data-table-td ">Methods, kits, and antibodies for detecting parathyroid hormone</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6743590">US6743590</a></td><td class="patent-data-table-td patent-date-value">Jun 26, 1999</td><td class="patent-data-table-td patent-date-value">Jun 1, 2004</td><td class="patent-data-table-td ">Scantibodies Laboratory, Inc.</td><td class="patent-data-table-td ">Methods for differentiating and monitoring parathyroid and bone status related diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6923968">US6923968</a></td><td class="patent-data-table-td patent-date-value">Aug 10, 2001</td><td class="patent-data-table-td patent-date-value">Aug 2, 2005</td><td class="patent-data-table-td ">Scantibodies Laboratory, Inc.</td><td class="patent-data-table-td ">Cyclase inhibiting parathyroid hormone antagonists or modulators and osteoporosis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7056655">US7056655</a></td><td class="patent-data-table-td patent-date-value">Nov 1, 2002</td><td class="patent-data-table-td patent-date-value">Jun 6, 2006</td><td class="patent-data-table-td ">Scantibodies Laboratory, Inc.</td><td class="patent-data-table-td ">Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7226749">US7226749</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 29, 2004</td><td class="patent-data-table-td patent-date-value">Jun 5, 2007</td><td class="patent-data-table-td ">Zahradnik Richard J</td><td class="patent-data-table-td ">Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7288253">US7288253</a></td><td class="patent-data-table-td patent-date-value">Aug 8, 2003</td><td class="patent-data-table-td patent-date-value">Oct 30, 2007</td><td class="patent-data-table-td ">Amgen Fremont, Inc.</td><td class="patent-data-table-td ">Antibodies directed to parathyroid hormone (PTH) and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7318925">US7318925</a></td><td class="patent-data-table-td patent-date-value">Sep 30, 2004</td><td class="patent-data-table-td patent-date-value">Jan 15, 2008</td><td class="patent-data-table-td ">Amgen Fremont, Inc.</td><td class="patent-data-table-td ">Methods of use for antibodies against parathyroid hormone</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7723042">US7723042</a></td><td class="patent-data-table-td patent-date-value">Sep 20, 2004</td><td class="patent-data-table-td patent-date-value">May 25, 2010</td><td class="patent-data-table-td ">Scantibodies Laboratory, Inc.</td><td class="patent-data-table-td ">Using parathyroid receptor epitope binding activity as a diagnostic indicator concentration of parathyroid hormone; diagnosing hyper/hypo-parathyroidism</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7795220">US7795220</a></td><td class="patent-data-table-td patent-date-value">Mar 19, 2003</td><td class="patent-data-table-td patent-date-value">Sep 14, 2010</td><td class="patent-data-table-td ">The General Hospital Corporation</td><td class="patent-data-table-td ">biologically active peptide for use in limiting undesired bone loss in a vertebrate at risk of such bone loss, in treating conditions that are characterized by undesired bone loss or by the need for bone growth, e.g. in treating fractures or cartilage disorders and for raising camp levels in cells</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7820393">US7820393</a></td><td class="patent-data-table-td patent-date-value">Jul 10, 2003</td><td class="patent-data-table-td patent-date-value">Oct 26, 2010</td><td class="patent-data-table-td ">Scantibodies Laboratory, Inc.</td><td class="patent-data-table-td ">Immunoglobulin which recognizes multiple antigenic peptides (MAP) for use in the diagnosis and differentiation between glandular and bone disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7851163">US7851163</a></td><td class="patent-data-table-td patent-date-value">Dec 18, 2000</td><td class="patent-data-table-td patent-date-value">Dec 14, 2010</td><td class="patent-data-table-td ">Immundiagnostik, Ag</td><td class="patent-data-table-td ">Method for determining the biologically effective parathyroid hormone activity in a sample</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7892749">US7892749</a></td><td class="patent-data-table-td patent-date-value">Jan 16, 2004</td><td class="patent-data-table-td patent-date-value">Feb 22, 2011</td><td class="patent-data-table-td ">Scantibodies Laboratory, Inc.</td><td class="patent-data-table-td ">Methods for differentiating and monitoring parathyroid and bone status related diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7893021">US7893021</a></td><td class="patent-data-table-td patent-date-value">Aug 9, 2002</td><td class="patent-data-table-td patent-date-value">Feb 22, 2011</td><td class="patent-data-table-td ">Scantibodies Laboratory, Inc.</td><td class="patent-data-table-td ">Parathyroid hormone antagonists and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7910544">US7910544</a></td><td class="patent-data-table-td patent-date-value">Jul 16, 2004</td><td class="patent-data-table-td patent-date-value">Mar 22, 2011</td><td class="patent-data-table-td ">The General Hospital Corporation</td><td class="patent-data-table-td ">Conformationally constrained parthyroid hormone (PTH) analogs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7943323">US7943323</a></td><td class="patent-data-table-td patent-date-value">Aug 15, 2003</td><td class="patent-data-table-td patent-date-value">May 17, 2011</td><td class="patent-data-table-td ">Scantibodies Laboratory, Inc.</td><td class="patent-data-table-td ">by detecting whole or non-fragmented parathyroid hormone and also a large non-whole peptide fragment hormone inhibitor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7959920">US7959920</a></td><td class="patent-data-table-td patent-date-value">Sep 6, 2006</td><td class="patent-data-table-td patent-date-value">Jun 14, 2011</td><td class="patent-data-table-td ">Scantibodies Laboratory, Inc.</td><td class="patent-data-table-td ">Methods of making and using antibodies directed to parathyroid hormone</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7985835">US7985835</a></td><td class="patent-data-table-td patent-date-value">Nov 13, 2006</td><td class="patent-data-table-td patent-date-value">Jul 26, 2011</td><td class="patent-data-table-td ">The General Hospital Corporation</td><td class="patent-data-table-td ">Bioactive peptides and peptide derivatives of parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8012694">US8012694</a></td><td class="patent-data-table-td patent-date-value">Sep 14, 2006</td><td class="patent-data-table-td patent-date-value">Sep 6, 2011</td><td class="patent-data-table-td ">Immutopics, Inc.</td><td class="patent-data-table-td ">Assay for the detection of phosphorylated PTH</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8143374">US8143374</a></td><td class="patent-data-table-td patent-date-value">Aug 3, 2007</td><td class="patent-data-table-td patent-date-value">Mar 27, 2012</td><td class="patent-data-table-td ">The General Hospital Corporation</td><td class="patent-data-table-td ">Polypeptide derivatives of parathyroid hormone (PTH)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8298770">US8298770</a></td><td class="patent-data-table-td patent-date-value">May 1, 2007</td><td class="patent-data-table-td patent-date-value">Oct 30, 2012</td><td class="patent-data-table-td ">Scantibodies Laboratory, Inc.</td><td class="patent-data-table-td ">Methods, kits, and antibodies for detecting parathyroid hormone</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8329409">US8329409</a></td><td class="patent-data-table-td patent-date-value">Aug 20, 2007</td><td class="patent-data-table-td patent-date-value">Dec 11, 2012</td><td class="patent-data-table-td ">Scantibodies Laboratory, Inc.</td><td class="patent-data-table-td ">Methods, kits, and antibodies for detecting parathyroid hormone</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8470543">US8470543</a></td><td class="patent-data-table-td patent-date-value">Jan 19, 2011</td><td class="patent-data-table-td patent-date-value">Jun 25, 2013</td><td class="patent-data-table-td ">Scantibodies Laboratory, Inc.</td><td class="patent-data-table-td ">Methods for differentiating and monitoring parathyroid and bone status related diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8568736">US8568736</a></td><td class="patent-data-table-td patent-date-value">Mar 21, 2008</td><td class="patent-data-table-td patent-date-value">Oct 29, 2013</td><td class="patent-data-table-td ">The General Hospital Corporation</td><td class="patent-data-table-td ">Polypeptide derivatives of parathyroid hormone (PTH)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8568737">US8568737</a></td><td class="patent-data-table-td patent-date-value">Aug 1, 2008</td><td class="patent-data-table-td patent-date-value">Oct 29, 2013</td><td class="patent-data-table-td ">The General Hospital Corporation</td><td class="patent-data-table-td ">Screening methods using G-protein coupled receptors and related compositions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8603977">US8603977</a></td><td class="patent-data-table-td patent-date-value">Jun 9, 2009</td><td class="patent-data-table-td patent-date-value">Dec 10, 2013</td><td class="patent-data-table-td ">The General Hospital Corporation</td><td class="patent-data-table-td ">Conformationally constrained parathyroid hormone (PTH) analogs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1455821A2?cl=en">EP1455821A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 3, 2002</td><td class="patent-data-table-td patent-date-value">Sep 15, 2004</td><td class="patent-data-table-td ">Quest Diagnostics Investments Incorporated</td><td class="patent-data-table-td ">Parathyroid hormone antibodies and related methods</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1659918A2?cl=en">EP1659918A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 8, 2003</td><td class="patent-data-table-td patent-date-value">May 31, 2006</td><td class="patent-data-table-td ">Abgenix, Inc.</td><td class="patent-data-table-td ">Antibodies directed to parathyroid hormone (pth) and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2003003986A2?cl=en">WO2003003986A2</a></td><td class="patent-data-table-td patent-date-value">Jul 3, 2002</td><td class="patent-data-table-td patent-date-value">Jan 16, 2003</td><td class="patent-data-table-td ">Quest Diagnostics Invest Inc</td><td class="patent-data-table-td ">Parathyroid hormone antibodies and related methods</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2004093902A1?cl=en">WO2004093902A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 19, 2003</td><td class="patent-data-table-td patent-date-value">Nov 4, 2004</td><td class="patent-data-table-td ">Percy Carter</td><td class="patent-data-table-td ">CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONES WITH α-HELIX STABILIZERS</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=FD5OBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc435/defs435.htm&usg=AFQjCNFivWgFr8pvtdk7qYLW9R7yxFP7Dg#C435S007100">435/7.1</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=FD5OBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc530/defs530.htm&usg=AFQjCNEOd3srpZKCSH0W93D5fiJ4_0S25w#C530S388240">530/388.24</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=FD5OBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc530/defs530.htm&usg=AFQjCNEOd3srpZKCSH0W93D5fiJ4_0S25w#C530S387200">530/387.2</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=FD5OBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc530/defs530.htm&usg=AFQjCNEOd3srpZKCSH0W93D5fiJ4_0S25w#C530S387100">530/387.1</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=FD5OBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc530/defs530.htm&usg=AFQjCNEOd3srpZKCSH0W93D5fiJ4_0S25w#C530S387900">530/387.9</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=FD5OBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc436/defs436.htm&usg=AFQjCNGx2wdEO-lMZYH5-JBwc-X_dDDKIg#C436S512000">436/512</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=FD5OBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07K0019000000">C07K19/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=FD5OBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=G01N0033780000">G01N33/78</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=FD5OBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07K0014635000">C07K14/635</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=FD5OBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07K0016240000">C07K16/24</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=FD5OBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07K0016260000">C07K16/26</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=FD5OBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=G01N0033530000">G01N33/53</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=FD5OBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0038220000">A61K38/22</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=FD5OBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0039000000">A61K39/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=FD5OBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0037040000">A61P37/04</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=FD5OBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07K14/635">C07K14/635</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=FD5OBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K39/00">A61K39/00</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">C07K14/635</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Apr 17, 2012</td><td class="patent-data-table-td ">FP</td><td class="patent-data-table-td ">Expired due to failure to pay maintenance fee</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20120229</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Feb 29, 2012</td><td class="patent-data-table-td ">LAPS</td><td class="patent-data-table-td ">Lapse for failure to pay maintenance fees</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Oct 10, 2011</td><td class="patent-data-table-td ">REMI</td><td class="patent-data-table-td ">Maintenance fee reminder mailed</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Nov 17, 2009</td><td class="patent-data-table-td ">FPB1</td><td class="patent-data-table-td ">Expired due to reexamination which canceled all claims</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Aug 23, 2007</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Apr 5, 2005</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20050204</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Aug 7, 2003</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Aug 27, 2002</td><td class="patent-data-table-td ">CC</td><td class="patent-data-table-td ">Certificate of correction</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Aug 6, 2002</td><td class="patent-data-table-td ">CC</td><td class="patent-data-table-td ">Certificate of correction</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Mar 5, 2001</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">PHARIS BIOTEC GMBH, GERMANY</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HAEMOPEP PHARMA GMBH;REEL/FRAME:011575/0543</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20010205</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">PHARIS BIOTEC GMBH KARL-WIECHERT-ALLEE 76 HANNOVER</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">PHARIS BIOTEC GMBH KARL-WIECHERT-ALLEE 76HANNOVER,</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HAEMOPEP PHARMA GMBH /AR;REEL/FRAME:011575/0543</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jan 5, 1998</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">HAEMOPEP PHARMA GMBH, GERMANY</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FORSSMANN, WOLF-GEORG;REEL/FRAME:008918/0687</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">19971203</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Mar 27, 1997</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">FORSSMANN,WOLF-GEORG, GERMANY</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ADERMANN, KNUT;HOCK, DIETER;MAGERLEIN, MARKUS;REEL/FRAME:008575/0835;SIGNING DATES FROM 19970302 TO 19970309</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_8a2b04e7bf975d5171d8e4c0b6365c7a.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U0_t7chMPgGlBdT8M5JbYEod70Dig\u0026id=FD5OBAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U0xWVuIVAJCbedKvpCv7J2SPSByTA\u0026id=FD5OBAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U2CpbtX6p3lu7DXNxtUQmIkPJ6VpQ","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Kit_for_detecting_active_human_parathyro.pdf?id=FD5OBAABERAJ\u0026output=pdf\u0026sig=ACfU3U3BVLR4Q92qvXTiPlWjhCo9aJW0cA"},"sample_url":"http://www.google.com/patents/reader?id=FD5OBAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>